NICE has been considering whether sufficent new evidence has emerged for the Appraisal Committee to be asked to understake a full update of TA327 Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; TA354 Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; TA261 Rivaroxaban for the treatment and secondary prevention of venous thromboembolism, and TA287 Rivaroxaban for the treatment of acute symptomatic pulmonary embolism with or without symptomatic DVT and the prevention of recurrent VTE.
No new evidence has emerged that is expected to substantially change the recommendations in TA261, TA287, TA327, TA341 and TA354. The clinical guideline for venous thromboembolic diseases is being updated, with an expected publication date of March 2020, including an update of anticoagulation treatment for deep vein thrombosis or pulmonary embolism. The current clinical guideline (CG144, last updated in 2015) does not include recommendations on dabigatran etexilate, apixaban, edoxaban or rivaroxaban. The scope for the guideline update states that it will cross-refer to and contextualise to relevant NICE technology appraisal guidance on pharmacological treatment for confirmed deep vein thrombosis (DVT) and pulmonary embolism (PE). The clinical guideline will also be able to place these treatments into the appropriate clinical context.
Consequently, NICE has decided that TA327, TA341, TA354, TA261 and TA287 should be moved to the static list.
Read full update: https://www.nice.org.uk/